Latest / Pharmacy Podcast Network / PBM Transparency, Is It Real? | PBM Reform Podcast
Transcript
- 0:07Speaker 1: Thanks for listening to the Pharmacy Podcast Network.
- 0:31Speaker 2: Welcome to the PBM Reform Podcast, where we dive deep
- 0:35Speaker 2: into the world of pharmaceutical benefit management, cutting through the
- 0:38Speaker 2: noise to uncover the truth. Since twenty nineteen, we've been
- 0:43Speaker 2: your go to source for the latest on how PBMs
- 0:46Speaker 2: impact patient care, drug pricing, and the very future of pharmacy.
- 0:51Speaker 2: Here we champion the role of pharmacists, the most knowledgeable
- 0:55Speaker 2: advocates for medication safety and expertise, as we expose and
- 1:01Speaker 2: generate discussions that are reshaping healthcare and explore how we
- 1:05Speaker 2: build a better payment system which focuses on advancing pharmacy care.
- 1:17Speaker 1: Welcome to the PBM Reform Podcast on the Pharmacy Podcast Network.
- 1:22Speaker 1: I'm your host Bret Rice, and I'm excited today because
- 1:26Speaker 1: we're doing things a little different. We're actually going to
- 1:28Speaker 1: talk to a PBM and see what's really different about them,
- 1:34Speaker 1: and so I want Alan to introduce himself and tell
- 1:37Speaker 1: us a little bit about his background and his experience
- 1:41Speaker 1: in the industry. So welcome to the show. Alan.
- 1:44Speaker 3: Awesome, Thanks Bret, I appreciate you having me on and yeah,
- 1:48Speaker 3: happy to be here. Like you mentioned, a little interesting,
- 1:51Speaker 3: probably having somebody from the you know, from the dark side,
- 1:54Speaker 3: talking about the dark side. But I do think we
- 1:57Speaker 3: bring a refreshing approach to pharmacy benefits and it's you know,
- 2:03Speaker 3: something that's near and dear to my heart is really
- 2:05Speaker 3: the pharmacy space. I'm a pharmacist by training. I started
- 2:10Speaker 3: out my career even before college working in a retail
- 2:13Speaker 3: pharmacy setting for a grocery chain and then through pharmacy school.
- 2:18Speaker 3: Actually fun too true, some a lie fact. I participated
- 2:24Speaker 3: in the NCPA Business Plan competition and at Idaho State
- 2:28Speaker 3: University and we were actually the winner of the competition,
- 2:32Speaker 3: and so independent pharmacies and you know, the value they
- 2:36Speaker 3: bring to the community is something that's actually really important
- 2:38Speaker 3: to me, which is, you know, maybe contrary to most
- 2:41Speaker 3: think of somebody that works at a PBM. But yeah,
- 2:46Speaker 3: started early in my career after pharmacy school focused in
- 2:49Speaker 3: managed care pharmacy. So I did a residency in managed
- 2:52Speaker 3: care pharmacy and then worked at a pass through transparent PBM.
- 2:56Speaker 3: I always joked that we were probably ten years too
- 2:59Speaker 3: soon in selling pass through and transparency in the PBM
- 3:02Speaker 3: space because nobody really cared about it from employer perspective
- 3:05Speaker 3: at the time, and you know, at that time, pharmacy
- 3:08Speaker 3: was less than ten percent of overall healthcare spend and
- 3:11Speaker 3: it just wasn't really a focus for benefit consultants and
- 3:14Speaker 3: employers and so but it was a great kind of entry,
- 3:19Speaker 3: I would say, into my career of getting into the
- 3:21Speaker 3: PBM space, learning how to do things the right way
- 3:23Speaker 3: and you know, how we could provide value within the
- 3:27Speaker 3: ecosystem to all parties. Shortly after some time there, we
- 3:30Speaker 3: were acquired by a much larger, publicly traded, you know,
- 3:35Speaker 3: more legacy type PBM, which was actually a great opportunity
- 3:39Speaker 3: for me in my career as well, because I was
- 3:40Speaker 3: able to really look under the hood and you know,
- 3:44Speaker 3: see the contract games that are played, the levers that
- 3:47Speaker 3: are pulled to really extract profits out of the ecosystem.
- 3:51Speaker 4: So spent some.
- 3:52Speaker 3: Time there kind of learning how to do things the
- 3:55Speaker 3: wrong way, if you will, and then after that joined
- 4:00Speaker 3: smith or X where I'm at today. I was on
- 4:02Speaker 3: the founding team here at smith or X. And we'll dive,
- 4:06Speaker 3: you know, deeper into too who we are and what
- 4:07Speaker 3: we do. But in short, we're a past through transparent
- 4:10Speaker 3: PBM that's really focused on helping patients, you know, get
- 4:14Speaker 3: drugs at the lowest costs sources supply.
- 4:17Speaker 1: Yeah, I appreciate that that background. But Alan, you know,
- 4:20Speaker 1: we've got to back up a little bit here and
- 4:23Speaker 1: you got to disclose what grocery store chain you were
- 4:26Speaker 1: working with as a staff pharmacist. Yeah.
- 4:28Speaker 3: Absolutely, So I'm local to Salt Lake City, Utah. So
- 4:33Speaker 3: I it was Smith's Food and Drug. It was eventually
- 4:37Speaker 3: acquired by Kroger, so it's part of the kind of
- 4:38Speaker 3: Kroger family of pharmacies.
- 4:40Speaker 4: But yeah, Smith's Food and Drug.
- 4:42Speaker 1: Yeh know it well. And then you your pharmacy school
- 4:46Speaker 1: was at I s U or where did you do
- 4:47Speaker 1: pharmacy school?
- 4:48Speaker 4: Yeah, Idaho State.
- 4:49Speaker 3: So I got my farm d at Idaho State University
- 4:52Speaker 3: in my mba while I was there as well, So I.
- 4:55Speaker 4: Was kind of been more interested in the business side
- 4:57Speaker 4: of pharmacy.
- 4:58Speaker 1: Excellent, excellent. That's great experience because that's that's one of
- 5:02Speaker 1: the things that that anyone in healthcare will tell you
- 5:06Speaker 1: that they wish they knew more about business too. So
- 5:09Speaker 1: I know some very successful, you know, plastic surgeons that
- 5:13Speaker 1: you would think, man, they're on top of it, right,
- 5:15Speaker 1: but they've gone back to business school because they need
- 5:19Speaker 1: to know how to run their business. Yeah, they are
- 5:21Speaker 1: very successful, but there's a lot of levers that have
- 5:24Speaker 1: to be pulled in order to keep more of that
- 5:28Speaker 1: that income that's coming in by being a surgeon or
- 5:31Speaker 1: in this case being a pharmacist. So what what are
- 5:34Speaker 1: a good combination to get your MBA as well as
- 5:37Speaker 1: as your farm d so. So, so tell me more
- 5:41Speaker 1: about the experience that you that you saw within the
- 5:45Speaker 1: big PBM organization. Let's let's dive into some of those
- 5:50Speaker 1: the things that you found to be maybe not the
- 5:54Speaker 1: most ethical. Let's let's jump into what those things are
- 5:58Speaker 1: and how you believe you're correcting them today.
- 6:01Speaker 4: Yeah, it's a great question.
- 6:02Speaker 3: So, you know, one of the the first I think
- 6:08Speaker 3: things that stand out is just the the manipulation of
- 6:11Speaker 3: drug pricing. So the past through transparent PBM that I
- 6:15Speaker 3: worked at, you know, clients chose us because they trusted us,
- 6:19Speaker 3: and so a lot of our contracts were you know,
- 6:21Speaker 3: very fair, simple, straightforward contracts, you know, handshake deals if
- 6:25Speaker 3: you will, where it's you know, we trust you to
- 6:26Speaker 3: be passed through and do the right thing and manage
- 6:28Speaker 3: our pharmacy benefits.
- 6:31Speaker 4: The unfortunate reality of that though, is once we were.
- 6:33Speaker 3: Acquired by the Legacy PBM, they saw those you know,
- 6:38Speaker 3: client contract opportunities as uh, you know, huge opportunities to
- 6:43Speaker 3: press or push forward more expensive claims, ultimately increasing their
- 6:49Speaker 3: drug costs at the behest of you know, reimbursing the
- 6:52Speaker 3: pharmacy you know, potentially very little. And so the you know,
- 6:56Speaker 3: the the culmination of of all of it was me
- 6:59Speaker 3: really having to have tough conversations with these employers that
- 7:02Speaker 3: trusted us in terms of you know, hey, what's happening
- 7:04Speaker 3: in my pharmacy trend?
- 7:05Speaker 4: Why is my spend going up?
- 7:06Speaker 3: And us really being kind of put in this position
- 7:09Speaker 3: of having to come up with the you know, the
- 7:11Speaker 3: typical industry adage of blaming pharma, right, drug price increases
- 7:14Speaker 3: and pharm of this and farm of that, and that's
- 7:16Speaker 3: why your spend's going up. But the reality of knowing
- 7:19Speaker 3: behind the scenes it was really just us making a
- 7:21Speaker 3: lot of money and you know maclist arbitrage games and
- 7:24Speaker 3: you know all the things that happened to manipulate pricing.
- 7:29Speaker 1: Yeah, that that is you know a clear today, are
- 7:34Speaker 1: more clear today with a lot of people in the industry,
- 7:38Speaker 1: but do employers really understand that and get that, or
- 7:42Speaker 1: are they still you know, buying the storyline that, oh,
- 7:46Speaker 1: just cost of medications are going up.
- 7:50Speaker 4: You know, it's it's a good question. I think with.
- 7:54Speaker 3: The recent I would say twenty twenty four and what
- 7:57Speaker 3: we've seen in twenty twenty five, there's been more mainstream
- 8:01Speaker 3: news and education and discussions around pharmacy benefits in these games.
- 8:06Speaker 1: Right.
- 8:06Speaker 3: You had last year the Wall Street Journal and the
- 8:09Speaker 3: New York Times publishing articles kind of trying to expose the.
- 8:12Speaker 4: PBMs and the vertical integration and the problems.
- 8:14Speaker 3: And you know, it was fairly bipartisan, and it's not
- 8:17Speaker 3: often that those two publications agree on things, but that's
- 8:21Speaker 3: one thing that they agreed on was this was an issue.
- 8:23Speaker 3: And so I think it's getting to the forefront. But however,
- 8:27Speaker 3: I will say there's still this, I think misconception on
- 8:32Speaker 3: the employer side in the industry that you have these
- 8:35Speaker 3: you know, really the Big four, Big five kind of
- 8:38Speaker 3: pharmacy benefit managers, and you know how they've got so
- 8:41Speaker 3: much scale and so much buying power, So how could
- 8:44Speaker 3: it be that you're pricing could be competitive or compared
- 8:47Speaker 3: to what they have today? And what's lost in that
- 8:51Speaker 3: discussion or that thought process is Yeah, there's no question
- 8:54Speaker 3: right that express Scripts as an example, probably has you know,
- 8:58Speaker 3: better pricing with Walgreens than I do as a PVM.
- 9:01Speaker 3: But the unfortunate reality is your players are not getting
- 9:04Speaker 3: access to that pricing, right, It's it's staying at express Scripts.
- 9:07Speaker 4: And so I think that's.
- 9:08Speaker 3: Where the the misconceptions come into play, where yeah, they
- 9:12Speaker 3: have big buying power, but you're not getting access to
- 9:14Speaker 3: that buying power.
- 9:15Speaker 1: Yeah. Yeah, I think one of the other misconceptions that
- 9:19Speaker 1: employers have too is that the carrier is paying a
- 9:26Speaker 1: different price for the medication, but they're really paying the
- 9:30Speaker 1: same price. They're basing it off of some listed price
- 9:33Speaker 1: of AWP or Whack Mac or whatever is being used
- 9:38Speaker 1: red book Er, Metispan. You know, the pricing is all there,
- 9:43Speaker 1: and even though they may be getting a discount from
- 9:47Speaker 1: their PBM partner, quite often it's a very small discount.
- 9:52Speaker 1: It's it's literally maybe five percent off of the retail
- 9:57Speaker 1: price market price, but yet that isn't getting passed on
- 10:02Speaker 1: to anyone that spread as being cap right there at
- 10:06Speaker 1: the PBM. Yeah, So tell me what transparency means to
- 10:11Speaker 1: you and your organization today.
- 10:15Speaker 3: Yeah, it's a great question, and I think you know
- 10:17Speaker 3: on the point you made about the issue with the
- 10:21Speaker 3: discounts and the price is not being passed through. I
- 10:24Speaker 3: think one fundamental flaw that exists today on the buy
- 10:30Speaker 3: side of pharmacy benefits, right employers picking pharmacy benefit managers
- 10:33Speaker 3: to be their vendors, is we have this kind of
- 10:37Speaker 3: archaic infrastructure that's set up based off of discounts.
- 10:41Speaker 4: Right.
- 10:41Speaker 3: As if I'm an employer and I say, oh, I
- 10:43Speaker 3: need to pick a pharmacy benefit manager, I go, I
- 10:46Speaker 3: don't know. You know, if I'm a mechanic shop, I
- 10:48Speaker 3: don't know anything about pharmacy benefits. Right, So I'm going
- 10:50Speaker 3: to go to my benefit consultant, my benefit broker, and
- 10:52Speaker 3: I'm going to say, hey, I need a pharmacy benefit manager,
- 10:54Speaker 3: and they're going to go through a diligence process. And
- 10:58Speaker 3: as part of that diligence process, the way that they're
- 11:00Speaker 3: comparing PBMs is using what we consider a discount based methodology. Right,
- 11:06Speaker 3: They're going to go to the PBM vendors and they're
- 11:07Speaker 3: going to say, hey, give me your AWP discount guarantees
- 11:10Speaker 3: on the pharmacy network pricing and give me your rebate
- 11:12Speaker 3: guarantees for you know, the discounts from the manufacturers, and
- 11:16Speaker 3: those are all aggregate discounts that come up and they
- 11:19Speaker 3: don't really correlate to spend. And the reason that is
- 11:22Speaker 3: is every year, if you talk to employers, they say, hey,
- 11:24Speaker 3: I renegotiate with my PBM every year and I get
- 11:26Speaker 3: better and better discounts. But if you look at their trend,
- 11:30Speaker 3: what they're spending on pharmacy continues to go up, and
- 11:32Speaker 3: so you know that they're just not it's they're not
- 11:36Speaker 3: connecting together. And so the what we feel strongly about,
- 11:40Speaker 3: as you mentioned, transparency, is a couple of things. It's
- 11:43Speaker 3: that evaluation process may have worked twenty years ago, it
- 11:46Speaker 3: doesn't work now with what's happening in drug mix and
- 11:49Speaker 3: biosimilars and generics and just all of the games that exist.
- 11:53Speaker 3: And so there really does need to be what we'd
- 11:55Speaker 3: consider a cost based evaluation process that really looks at
- 11:59Speaker 3: what the employer, which is how much they're spending. Right,
- 12:02Speaker 3: you spend a million dollars this year on pharmacy benefits,
- 12:05Speaker 3: What am I going to spend next year? And that's
- 12:07Speaker 3: how the evaluation process should be done. And in order
- 12:10Speaker 3: to be able to do that, the long way of
- 12:12Speaker 3: getting to your question on transparency, I think you have
- 12:17Speaker 3: to be able to partner with somebody that's that's willing
- 12:19Speaker 3: to disclose really all aspects of the supply chain.
- 12:23Speaker 4: Right.
- 12:24Speaker 3: For us, that means we've got, you know, contracts and
- 12:27Speaker 3: discounts we get from drug manufacturers and the employer they're
- 12:30Speaker 3: paying the bill, so they should know, right, what is
- 12:32Speaker 3: that rebate or what is that discount that I'm getting
- 12:34Speaker 3: on my branded drug, let's sage audience. They also should know,
- 12:38Speaker 3: you know, what is the contract that you're holding with
- 12:40Speaker 3: Walgreens on my medication, and you should be able to
- 12:42Speaker 3: get access to that data and understand exactly what was paid.
- 12:46Speaker 3: So full access to data, I think is the first
- 12:48Speaker 3: part of transparency. The other piece of that is, you know,
- 12:52Speaker 3: there's a number of ways for patients to be able
- 12:55Speaker 3: to get their medications right, There's different pharmacies they can
- 12:58Speaker 3: go to, there's different drugs that they could use, first generics,
- 13:01Speaker 3: so they should also be able to know, you know,
- 13:03Speaker 3: what is that lowest cost pathway right for my medication
- 13:06Speaker 3: and are you helping my patient get there?
- 13:07Speaker 4: I think those are two important key aspects to what
- 13:10Speaker 4: transparency should be.
- 13:12Speaker 1: Yeah, so how do you ensure that that happens? And
- 13:15Speaker 1: let's let's talk specifically about you know, Smith r X
- 13:18Speaker 1: where you're at today, because it it seems, you know,
- 13:23Speaker 1: if you look at the history of PBMs, you go
- 13:25Speaker 1: back to the sixties, there was a real benefit to
- 13:29Speaker 1: having that PBIM in there to help control costs. But
- 13:32Speaker 1: then as profits and revenues started coming in the door,
- 13:37Speaker 1: that got pretty nice. And and then you know, private
- 13:41Speaker 1: equity got involved and everyone needed their return on investment.
- 13:45Speaker 1: And and so how do you how do you ensure
- 13:48Speaker 1: that transparency stays in place and that you know, greed
- 13:53Speaker 1: or the the love of money and income doesn't take
- 13:58Speaker 1: over and uh and start to you know, move some
- 14:01Speaker 1: of those levers again.
- 14:03Speaker 3: Yeah, I think the first thing that needs to happen,
- 14:06Speaker 3: right as a as a pharmacy benefit manager, is you
- 14:09Speaker 3: have to remove those incentives.
- 14:10Speaker 4: And so you mentioned the vertical integration.
- 14:12Speaker 3: Right, that's that's the kind of first first step down
- 14:18Speaker 3: a slippery slope.
- 14:19Speaker 1: Right.
- 14:19Speaker 3: If I'm if I'm a pharmacy benefit manager and I
- 14:22Speaker 3: own pharmacies, whether it's a mel order, a specialty pharmacy right,
- 14:25Speaker 3: My incentives are I'm going to drive volume to my
- 14:27Speaker 3: my owned asset, and how do I best do that?
- 14:30Speaker 3: And so you look at even something as simple that's
- 14:33Speaker 3: you know, very commonplace today. But is you know this,
- 14:36Speaker 3: this concept of specialty drugs right, like that was really
- 14:39Speaker 3: driven by the fact of, Hey, I'm a PBM and
- 14:41Speaker 3: I'm going to own a pharmacy. How do I how
- 14:43Speaker 3: do I come up with a reason to put volume
- 14:45Speaker 3: to that pharmacy. Oh, I'm going to come up with
- 14:47Speaker 3: this concept of specialty drugs, and I'm going to classify
- 14:49Speaker 3: these drugs as special for no reason really in particular,
- 14:53Speaker 3: I'm going to make all of those special drugs go
- 14:54Speaker 3: to my pharmacy. And so, first and foremost, if a
- 14:58Speaker 3: PBM owns pharmacy, is right, that creates an opportunity, not
- 15:02Speaker 3: saying every PBM does that, but it creates an opportunity
- 15:04Speaker 3: for those misaligned incentives. I think the other piece that
- 15:07Speaker 3: exists is getting back to this cost based construct is one,
- 15:13Speaker 3: how is the PBM being compensated? Right If they're making
- 15:16Speaker 3: money in any way, shape or form that's correlated to
- 15:20Speaker 3: the price of drugs, right, Ultimately that's going to lead
- 15:23Speaker 3: to drug prices increasing right as it stands today, Right,
- 15:26Speaker 3: the traditional kind of legacy PBM model is, I mean
- 15:30Speaker 3: to takes spread pricing through the network pharmacies. So my
- 15:33Speaker 3: incentive is if drug pricing grows up, I can increase
- 15:36Speaker 3: that spread that I take similar on the rebate side
- 15:38Speaker 3: as well.
- 15:39Speaker 4: Right.
- 15:39Speaker 3: PBMs say that they're controlling right pharma, and they're negotiating
- 15:44Speaker 3: good discounts with them, and they're kind of keeping costs down,
- 15:46Speaker 3: and I think that's true to some extent, but at
- 15:49Speaker 3: the same time, like.
- 15:49Speaker 4: They're not really sad if prices go up.
- 15:51Speaker 3: Right, And you look at golp ones is a great
- 15:53Speaker 3: example of this, right, this huge influx of utilization of
- 15:56Speaker 3: glp ones. Yes, it's a problem, but at the same time,
- 16:01Speaker 3: the big PBMs aren't too sad about it because they're
- 16:04Speaker 3: able to take a percentage of the rebates that are
- 16:06Speaker 3: flowing through, and so you know, more volume means more
- 16:08Speaker 3: revenue for them, right.
- 16:11Speaker 1: Right, Yeah, So you know it's interesting that you bring
- 16:15Speaker 1: up those incentives, right and obviously mail order fulfillment, uh,
- 16:21Speaker 1: you know, taking the patient away from a community pharmacy
- 16:25Speaker 1: so that the PBM can you know, dispense that the
- 16:28Speaker 1: maintenance medication from their own pharmacy, So not just retail pharmacy,
- 16:33Speaker 1: you know connection, but now taking the taking the patient
- 16:38Speaker 1: completely out of retail and doing fulfillment from their mail
- 16:41Speaker 1: orders is certainly a big, big problem, you know. And
- 16:44Speaker 1: anytime that I look at, you know, a a client
- 16:48Speaker 1: and they want to do an evaluation on on their
- 16:52Speaker 1: you know, drug spend, that's one thing that we always
- 16:55Speaker 1: tell them look at is, hey, you know, we we
- 16:58Speaker 1: have statistics on the percentage of refills a patient should
- 17:01Speaker 1: be getting, at least for my segment of the industry,
- 17:05Speaker 1: and we know what those averages are nationally, and if
- 17:08Speaker 1: they're not seeing those refills, they're absolutely getting, you know,
- 17:12Speaker 1: siphoned off to meloder pharmacy. And I know it from
- 17:15Speaker 1: personal experience, not just from hearsay. You know, I was
- 17:19Speaker 1: on a maintenance medication. I love spicy food, allan, I've
- 17:23Speaker 1: always been a fan of Mexican food, but that causes
- 17:27Speaker 1: some assid reflux, and so I was on an omeprazol
- 17:30Speaker 1: medication and had you know, had several refills on that,
- 17:34Speaker 1: and of course I got the letter from my PBM
- 17:38Speaker 1: stating it almost looked like it was mandatory that I
- 17:42Speaker 1: needed to get my refills through their meloorder, and it
- 17:46Speaker 1: took me literally about five or six phone calls to
- 17:51Speaker 1: get me removed off of that meloder list so that
- 17:54Speaker 1: I could go to my local community pharmacy to get
- 17:57Speaker 1: that refill.
- 18:00Speaker 3: And it's really unfortunate, right, I think, you know, back
- 18:03Speaker 3: to your question about you know, what makes Smith or
- 18:06Speaker 3: X different is we really see the community pharmacies and
- 18:10Speaker 3: independent pharmacies is kind of allies in our fight, right.
- 18:13Speaker 3: I think they provide a huge benefit to the community.
- 18:17Speaker 3: And you know, again, as I mentioned in my intro,
- 18:19Speaker 3: I think being involved with NCPA early on in my
- 18:22Speaker 3: career and participating in the business plan competition, I think
- 18:25Speaker 3: it just makes it near and dear to my heart.
- 18:26Speaker 3: But the last thing we want to see is these
- 18:29Speaker 3: independent pharmacies right going out of business, which is what's happening.
- 18:32Speaker 3: And so one thing that we've done, and we've kind
- 18:34Speaker 3: of set out to do, is really recontract and kind
- 18:38Speaker 3: of reimagine our pharmacy network in a way that really
- 18:43Speaker 3: gets back to that some version of a cost based
- 18:47Speaker 3: type of contract with these pharmacies where it's hey, you're
- 18:50Speaker 3: doing a valuable job, let's pay you a fixed dispensing
- 18:52Speaker 3: feed for the work you're doing, and let's reimburse you
- 18:55Speaker 3: reasonably for the ingredient costs. And let's keep those two
- 18:57Speaker 3: things separate. Right, Whether it's you know, NEDAK exists, there's
- 19:01Speaker 3: you know, plenty of flaws and issues that we can
- 19:03Speaker 3: talk about with that over the last.
- 19:04Speaker 4: Couple of years.
- 19:05Speaker 3: There's you know, pack, there's acquisition costs plus like, there's
- 19:08Speaker 3: all these different ways, and we're willing to work with
- 19:10Speaker 3: you on.
- 19:11Speaker 4: Whatever one you're the most comfortable with as a pharmacy.
- 19:13Speaker 3: But let's let's move away from this idea of like
- 19:15Speaker 3: AWP discounts and MAC and you know overall generic effective
- 19:18Speaker 3: rates and all the games that make it so there's
- 19:20Speaker 3: going to cross subsidization across drugs.
- 19:23Speaker 1: Yeah, and you mentioned the pharmacy closures, you know of
- 19:27Speaker 1: our founder of the Pharmacy podcast Network, Todd, reported recently
- 19:31Speaker 1: that there's an independent going out of business one per
- 19:35Speaker 1: day now, so at that fast of a rate. So
- 19:39Speaker 1: it's really a sad state of affairs for especially for
- 19:42Speaker 1: the independence. But we've also seen some of the chains
- 19:45Speaker 1: start to shrink as well, and their size is you know,
- 19:52Speaker 1: is there anything, is there any correlation between are they
- 19:55Speaker 1: are they like eating their own with the with the
- 19:58Speaker 1: PBM revenue.
- 20:01Speaker 4: Yeah, it's it's a good question.
- 20:02Speaker 3: That's one thing that has been interesting is we we
- 20:05Speaker 3: kind of set down this path in the end of
- 20:08Speaker 3: twenty twenty three and moving into twenty twenty four of
- 20:10Speaker 3: recontracting our pharmacy network. And one thing that's actually been
- 20:14Speaker 3: fascinating to me is some of these larger chainses we've
- 20:17Speaker 3: gone to them and we've said, hey, we want to
- 20:19Speaker 3: do a different approach, and this is actually better for
- 20:21Speaker 3: you because now you can actually, you know, consistently budget
- 20:24Speaker 3: and know exactly how much you're going to make on
- 20:26Speaker 3: every single prescription claim. The actual resistance that we're getting
- 20:30Speaker 3: and like their unwillingness to switch models because of I
- 20:35Speaker 3: guess you know that's I guess you know what you know.
- 20:37Speaker 4: And part of it's probably.
- 20:39Speaker 3: The ill sentiments that exist between pharmacies and PBMs, and
- 20:43Speaker 3: they feel like, you know, there's got to be some
- 20:45Speaker 3: catch to it, right, and at the end of the day,
- 20:47Speaker 3: there's they're going to get the raw end of the deal.
- 20:49Speaker 3: But the reality is is we just want to make
- 20:51Speaker 3: it fair for inequitable for everyone. And it's it's been
- 20:54Speaker 3: really hard for them to trust us.
- 20:56Speaker 1: Yeah, yeah, I understand. So so tell me about your
- 21:00Speaker 1: reporting then, for you know, transparency and is it regular reporting.
- 21:04Speaker 1: Does it you know, include drug pricing, does it include
- 21:08Speaker 1: rebate earnings? Tell me about your reporting.
- 21:12Speaker 4: Yeah. So.
- 21:12Speaker 3: One thing that's unique to Smith or X, right is
- 21:14Speaker 3: there's many pass through PBMs that exist in the market.
- 21:17Speaker 4: There's a we're we're kind of coining.
- 21:19Speaker 3: The more innovative, kind of forward thinking PBMs as modern PBMs,
- 21:24Speaker 3: and Smith X isn't unique.
- 21:26Speaker 4: There's many of them out there. But one thing that
- 21:28Speaker 4: I will say that.
- 21:29Speaker 3: That is definitely unique is you use the word pass
- 21:33Speaker 3: through and that and in essence means, right, what I'm
- 21:36Speaker 3: invoicing the client is what I paid the pharmacy, Right,
- 21:39Speaker 3: I'm passing through that amount. What's interesting though, that we
- 21:43Speaker 3: found and I think I would challenge, you know, anybody
- 21:46Speaker 3: to reach out otherwise. But I think we're the only
- 21:48Speaker 3: PBM that exists today that is actually passing through and
- 21:52Speaker 3: paying the pharmacy. So passing through and building the client
- 21:55Speaker 3: what we have contracted with the pharmacy, meaning every client
- 21:58Speaker 3: with Smith or X, whether you're you know, a fifty
- 22:01Speaker 3: life group, or a fifty thousand life group, you're getting
- 22:03Speaker 3: that exact same pricing.
- 22:04Speaker 4: And so smith Rex, you.
- 22:06Speaker 3: Know, literally has one price per drug per pharmacy, whereas
- 22:11Speaker 3: a lot of PBMs that claim to be passed through
- 22:14Speaker 3: or are passed through, they're passing through what's paid and
- 22:16Speaker 3: not necessarily what's contracted. Meaning you know, I could have
- 22:21Speaker 3: you know, fifty different pricing schedules with with Walgreens, and
- 22:25Speaker 3: depending on the client size or who they are, what
- 22:27Speaker 3: they've negotiated with me, right, there could be fifty different prices.
- 22:32Speaker 3: And so to get to your question about reporting, we
- 22:36Speaker 3: feel like the client's paying the claims, right, it's their data,
- 22:40Speaker 3: and so they can log into our portal. They can
- 22:42Speaker 3: download claims data at any point in time, get the
- 22:45Speaker 3: raw NCPDP level claims pricing information. They can also see
- 22:49Speaker 3: performance reporting to know, you know, how the plan's performing
- 22:53Speaker 3: on a per number per month basis rebate reporting as
- 22:56Speaker 3: well as you mentioned, so they can see down to
- 22:58Speaker 3: the drug level. I'm getting this much rebate on jority
- 23:01Speaker 3: and so really we want them to know what's happening
- 23:03Speaker 3: with their plan. But one thing that's important is when
- 23:05Speaker 3: they look at that pricing on the pharmacy claim information.
- 23:09Speaker 3: That's the same pricing for everybody, and so they truly
- 23:11Speaker 3: have access to what smith Rex's pricing is.
- 23:15Speaker 1: Okay, how do you handle rebates, so manufacturers rebates, are
- 23:20Speaker 1: those passed through as well? Or is a percentage of
- 23:23Speaker 1: it passed through?
- 23:24Speaker 3: Yeah, so that's another great point, and there's lots of
- 23:28Speaker 3: versions when we say we pass through you know, one
- 23:30Speaker 3: hundred percent of rebates, Well, there's plenty of games that
- 23:32Speaker 3: are played in terms of, well, how do you define
- 23:33Speaker 3: a rebate.
- 23:34Speaker 4: And is it an admin fee? Is it a clinical fee?
- 23:37Speaker 3: The simplest way to say, anything that we get from
- 23:39Speaker 3: the manufacturer is the clients, right, it's not our you know,
- 23:44Speaker 3: we didn't pay for the cost of the drug and
- 23:46Speaker 3: so we shouldn't be taking any part of that. And
- 23:48Speaker 3: so the client gets you know, passed through everything that
- 23:51Speaker 3: we receive from the manufacturer. We do work up. Unfortunately,
- 23:56Speaker 3: It's it's interesting when you look at the big PBMs
- 23:59Speaker 3: and the market share that out there. The common quote is,
- 24:03Speaker 3: you know, eighty percent of the market is held by
- 24:06Speaker 3: the big three. But what's interesting when you look at
- 24:08Speaker 3: the rebates side, the reality is it's closer to one
- 24:11Speaker 3: hundred percent because the drug manufacturers have gotten to the
- 24:14Speaker 3: point of saying, you know, they won't work with anybody.
- 24:17Speaker 3: But they're called GPOs right A, scent, Zinc and MSR
- 24:20Speaker 3: that are owned by the big three PBMs and they
- 24:23Speaker 3: handle all the rebates and manufacture contracting, and so just
- 24:26Speaker 3: like every PBM, we're forced to go up through those
- 24:28Speaker 3: GPOs and it's one thing that we're we're trying to change.
- 24:32Speaker 3: We're having ongoing conversations with drug manufacturers about you know, hey,
- 24:36Speaker 3: we want to do things differently. There's you know, all
- 24:38Speaker 3: the flaws with the three GPOs that exist, and there's
- 24:41Speaker 3: a lot of fear on pharmacide to do things differently
- 24:44Speaker 3: because of retaliation, which is unfortunately sad. And so we've
- 24:48Speaker 3: really taken the approach of looking at things differently from
- 24:51Speaker 3: the sense of rebates and drugs and branded drugs and
- 24:55Speaker 3: looking at really pushing farmer to say, listen, let's just
- 24:59Speaker 3: get rid of this idea rebates and we're really focused
- 25:01Speaker 3: on the low list price. Right, Let's get the savings
- 25:04Speaker 3: at the point of sell. That benefits the patient, it
- 25:06Speaker 3: benefits the plan. There's not this you know, kickback that
- 25:09Speaker 3: comes six months later and there's some manufacturers that are
- 25:12Speaker 3: open to it than others that are they're less open,
- 25:15Speaker 3: but it's it's becoming more and more a topic of conversation.
- 25:20Speaker 3: Is the Big three GPOs are gaining much more power
- 25:23Speaker 3: than they had before.
- 25:24Speaker 1: Yeah, yeah, let's let's get into formulary because you know
- 25:29Speaker 1: that's another game, right that can be played, is putting
- 25:33Speaker 1: out a formulary that's going to have, you know, more
- 25:35Speaker 1: expensive drugs and that the need to be and isn't
- 25:40Speaker 1: you know, always the most cost effective treatment plan. How
- 25:43Speaker 1: does smith RX handle formularies.
- 25:46Speaker 3: Yeah, so when you think about the concept of formulaties,
- 25:50Speaker 3: like you said that, they were largely kind of brought
- 25:53Speaker 3: about under I think well intentioned ideas of controlling costs. Right,
- 25:58Speaker 3: You've got drug can categories that you know, disease states
- 26:01Speaker 3: and treatments that exists, and there's multiple medications and so
- 26:04Speaker 3: let's kind of stratify those medications by tears and having
- 26:09Speaker 3: the more cost effective products that have a lower cost
- 26:12Speaker 3: share for patients. So that concept still largely exists within
- 26:17Speaker 3: smith or X today. That being said, we are hyper
- 26:21Speaker 3: focused on whenever we can leverage the upfront.
- 26:25Speaker 4: Savings, we're going to take advantage of that.
- 26:27Speaker 3: And so what doesn't exist within Smith or X is
- 26:30Speaker 3: those scenarios of you know, a branded drug being preferred
- 26:33Speaker 3: over a generic simply because there's a rebate that is available.
- 26:38Speaker 3: And that's another important piece is there's even within you know,
- 26:41Speaker 3: a disease stat or of medication. There's many different ways
- 26:45Speaker 3: that a patient can access those medications, and so we
- 26:47Speaker 3: do have a whole team of patient advocates to help
- 26:52Speaker 3: navigate these patients to the lowest cost sources supply. We
- 26:55Speaker 3: call it our Drug Pathways Engine, where it's it's a
- 26:58Speaker 3: technology that we've built. As a prescription claim comes into
- 27:01Speaker 3: our system, it identifies, you know, opportunities for savings and
- 27:05Speaker 3: so in those situations, it flags a series of workflows
- 27:10Speaker 3: and engagement from our team two patients saying, hey, you're
- 27:13Speaker 3: taking this medication, did you know there was a lower
- 27:15Speaker 3: cost alternative available, or did you know there's you know,
- 27:17Speaker 3: manufacturer coupons that we could use to help lower your
- 27:20Speaker 3: costs and let's help you get set up with those.
- 27:22Speaker 3: Or you know you're at a very expensive, big box pharmacy.
- 27:25Speaker 3: Did you know we could get you to an independent pharmacy.
- 27:27Speaker 3: Let's get you an independent pharmacy around the corner that's
- 27:30Speaker 3: less expensive, and we'll help facilitate the transfer and the
- 27:32Speaker 3: transaction there. And so going even beyond you know, formulay
- 27:37Speaker 3: kind of think of that as like the baseline, but
- 27:38Speaker 3: really going beyond that and helping optimize therapiest as well.
- 27:43Speaker 1: Okay, and do clients, you know, have a full list
- 27:48Speaker 1: of the drugs available and are there any fees for
- 27:52Speaker 1: managing that formulary or is it all part of the service.
- 27:56Speaker 4: It's all part of the service.
- 27:57Speaker 3: So we we charge a flag permember per month fee
- 28:02Speaker 3: for our core services and core offerings, and then there's
- 28:05Speaker 3: an additional fee for our patient navigation services that's also
- 28:10Speaker 3: per member per month that has an ROI.
- 28:13Speaker 4: Associated with it.
- 28:14Speaker 3: But we really consider you know, formulay management, prior authorization,
- 28:18Speaker 3: step therapy, you know, all rebates, network contracting, all that's
- 28:22Speaker 3: the blocking and tackling that a PBM should be doing.
- 28:25Speaker 3: There should be Nickelin dining fees associated with those. It's
- 28:28Speaker 3: it's just part of the service fee that we charge.
- 28:31Speaker 1: Okay, We've talked a lot about clients, which are the employers.
- 28:36Speaker 1: Let's talk you know, this is the Pharmacy Podcast Network.
- 28:40Speaker 1: How are you received by the community pharmacy industry and
- 28:46Speaker 1: what are the differentiations there of why a pharmacy would say, okay,
- 28:50Speaker 1: we'll take we'll take this plan.
- 28:53Speaker 4: Yeah, that's a great question.
- 28:54Speaker 3: So again talking about maybe subtle differences between the modern
- 28:59Speaker 3: PBMs and kind of middle market PBMs. One thing that's
- 29:02Speaker 3: unique with Smith is a lot of the middle market PBMs,
- 29:06Speaker 3: to be able to compete, end up renting or leasing
- 29:09Speaker 3: their pharmacy network. And typically when they do that, the
- 29:13Speaker 3: main players that exist are the big three PBMs, so
- 29:16Speaker 3: optim Express, Scripts, and CBS, and so there always ends
- 29:19Speaker 3: up being some irony in that, you know, you're a
- 29:21Speaker 3: pass through transparent PBM, but then your back end network
- 29:25Speaker 3: that's contracted with the pharmacies is is maybe not the best,
- 29:27Speaker 3: you know, the best player in the game. From the beginning,
- 29:31Speaker 3: we set out to really control our own destiny and
- 29:34Speaker 3: we feel like that was important, and so we have
- 29:36Speaker 3: our own pharmacy network that we've contracted, which gives us
- 29:39Speaker 3: the flexibility to be able to put together unique pricing
- 29:43Speaker 3: arrangements and make sure that we're fairly reimbursing independent pharmacies
- 29:48Speaker 3: and community pharmacies.
- 29:49Speaker 4: And a good example of this.
- 29:50Speaker 3: Is we actually have a number of employer con clients
- 29:55Speaker 3: that are concentrated in a certain area up in Montana,
- 30:00Speaker 3: and we were actually able to work with those employers
- 30:02Speaker 3: to say, hey, look, you know the the independent pharmacies
- 30:05Speaker 3: and community pharmacies in your towns, you know are you know,
- 30:09Speaker 3: these are smaller towns, and these are people that you
- 30:11Speaker 3: work with on a daily basis, probably go to church
- 30:13Speaker 3: with them and see them. Right, and under the current model, right,
- 30:17Speaker 3: they're probably being reimbursed through their p SAOs less than
- 30:20Speaker 3: what's favorable. And so what we would like to do,
- 30:22Speaker 3: if you're okay with it, is the employer, right, you're
- 30:24Speaker 3: going to pay a little bit more, but would you
- 30:26Speaker 3: be willing to give them what we'd consider more of
- 30:28Speaker 3: a fair reimbursement setup. And they were actually very excited
- 30:31Speaker 3: to do it, and you know, it slightly increased all
- 30:33Speaker 3: of their costs, but it was enough that it kept
- 30:36Speaker 3: the pharmacies in a position of staying open really to
- 30:39Speaker 3: be frank, but then also you know, still provided that
- 30:43Speaker 3: value in that service. Right, They're the employers were willing
- 30:45Speaker 3: to pay a little bit more for the service that
- 30:47Speaker 3: their employees were getting and their patients were getting, and
- 30:50Speaker 3: that's something that we've been looking to replicate really across
- 30:53Speaker 3: the country because again, it's when you talk to the
- 30:57Speaker 3: employers about it, they're okay paying a little bit more
- 30:59Speaker 3: money because they know this.
- 31:00Speaker 4: Service is better at these pharmacies.
- 31:01Speaker 1: Yeah.
- 31:02Speaker 4: Well, in short.
- 31:03Speaker 3: Answer your question, my hope would be and our goal
- 31:05Speaker 3: would be that if you were to ask any community
- 31:07Speaker 3: pharmacy that's you know, contracted with Smith or X, they'd say, yeah,
- 31:11Speaker 3: they're they're a fair pharmacy benefit manager and we like
- 31:14Speaker 3: to work with them. And if that's not the case,
- 31:15Speaker 3: then we'd love to talk with them because we want
- 31:18Speaker 3: them to fill that way, right.
- 31:20Speaker 1: Yeah, well we'll leave your cell your personal cell number
- 31:23Speaker 1: in the show notes so they can all call you.
- 31:27Speaker 1: But no, seriously, though, you know, that's great to hear
- 31:31Speaker 1: that that you know, you have made those relationships between
- 31:36Speaker 1: the employer and community pharmacies, and you know, we've always
- 31:40Speaker 1: I've always been a very big advocate of you know,
- 31:43Speaker 1: why wait around for hours or days to get your
- 31:46Speaker 1: medication when you know an independently owned community pharmacy can
- 31:50Speaker 1: fill that for you in ten minutes. So yeah, so
- 31:53Speaker 1: there's some some real advantages there. So I'm glad that
- 31:56Speaker 1: that that Smith our ex has recognized that. So alan,
- 32:02Speaker 1: are there other key differentiators, you know, speaking to the pharmacy,
- 32:07Speaker 1: you know, community pharmacies and why you know, what makes
- 32:11Speaker 1: you better than any of your competitors.
- 32:15Speaker 4: Yeah, I think really in short.
- 32:17Speaker 3: Right, we want to bring pharmacy benefit managers back to
- 32:22Speaker 3: what they were intended to do, right. I think there's
- 32:26Speaker 3: there's some you know, pharmacy advocates out there that are
- 32:29Speaker 3: strongly advocating for right like PBMs shouldn't exist and they're
- 32:32Speaker 3: just adding extra cost to the you know, their middleman
- 32:35Speaker 3: and adding.
- 32:35Speaker 4: Extra cost to the healthcare system.
- 32:37Speaker 3: And I think that that's true, right for the legacy PBMs,
- 32:41Speaker 3: But there is value here, right in terms of just
- 32:44Speaker 3: facilitating the ease of that transaction between the pharmacy and
- 32:47Speaker 3: the employer, and also the data that's captured and the
- 32:50Speaker 3: reporting that's captured. As you look beyond just the pharmacy
- 32:54Speaker 3: benefit and you talk about just healthcare in general and
- 32:56Speaker 3: stop loss reporting and reinsurance and all of the things
- 33:00Speaker 3: that exist, Like there's there's a need for that transaction
- 33:03Speaker 3: to be facilitated by a pharmacy benefit manager.
- 33:06Speaker 4: There's also a.
- 33:07Speaker 3: Need for a pharmacy benefit manager to build a niche
- 33:11Speaker 3: of helping.
- 33:12Speaker 4: Navigate these patients.
- 33:13Speaker 3: Right, we have we have access and control of these
- 33:15Speaker 3: patients in terms of where they can go. And healthcare
- 33:18Speaker 3: is confusing and pharmacies even more confusing, and so we
- 33:20Speaker 3: can provide that need and helping navigate them to that
- 33:23Speaker 3: lowest cost sources supply, which in many cases, right is
- 33:25Speaker 3: community pharmacies. And so I think that from a pharmacy standpoint,
- 33:31Speaker 3: the main kind of take home message is we want
- 33:34Speaker 3: to be an ethical, honest, you know, good PBM in
- 33:38Speaker 3: a place that's you know, maybe not the most ethical,
- 33:41Speaker 3: and and be a good partner. And that's probably our
- 33:44Speaker 3: key differentiator is like we're here to work with you.
- 33:47Speaker 3: You know, as you were mentioning connecting pharmacies with employers,
- 33:51Speaker 3: we see a huge opportunity there as well, because you know,
- 33:54Speaker 3: you look at these local communities where these community pharmacies exist,
- 33:58Speaker 3: and many of them know this eos and CFOs of
- 34:01Speaker 3: their local employers, and many of them are stuck with
- 34:03Speaker 3: the big three PBMs, and we're happy to kind of
- 34:06Speaker 3: help them navigate the you know, employer broker health benefit
- 34:11Speaker 3: ecosystem of like, hey, how can we get them connected
- 34:13Speaker 3: with not necessarily Smith, but maybe another modern PBM as
- 34:16Speaker 3: well that can help that employer get.
- 34:19Speaker 4: You fairly reimbursed.
- 34:21Speaker 3: And we're more than happy to facilitate that because we
- 34:23Speaker 3: think there's it really is going to take a grassroots effort.
- 34:25Speaker 3: I think there's a lot of talk on the Hill
- 34:27Speaker 3: about you know, PBM reform and bands on spread pricing
- 34:31Speaker 3: and this, that and the other, and I think there
- 34:34Speaker 3: might be some value that comes from that. But the
- 34:36Speaker 3: end of the day, these these massive, vertically integrated, publicly
- 34:39Speaker 3: traded companies, like they're going to find the loopholes, and
- 34:43Speaker 3: you know, Washington can only move so fast, so we're
- 34:45Speaker 3: going to get something, some level of legislation put forth,
- 34:47Speaker 3: and they're you know, we're playing checkers and they're playing chess,
- 34:50Speaker 3: so they're going to be four steps ahead of us.
- 34:53Speaker 3: So it really is going to take, you know, getting
- 34:55Speaker 3: employers to make an educated decision. I think you had
- 34:58Speaker 3: on your podcast a little while go Representative Austin class
- 35:01Speaker 3: and he actually put together a kind of a Venn
- 35:04Speaker 3: diagram that talks about PBM reform and kind of his vision,
- 35:08Speaker 3: and I think he puts it perfectly, and that there's
- 35:10Speaker 3: public litigation, there's legislation, and then there's competition. And like
- 35:14Speaker 3: where those three overlap is where you get reform right
- 35:17Speaker 3: and you have the litigation is what gets employers thinking.
- 35:21Speaker 3: And that's what we're seeing with the J and J,
- 35:23Speaker 3: the Wells Fargo, now the JP Morgan lawsuits right, Employers
- 35:26Speaker 3: are thinking twice, like, hey, am I doing my fiduciary duty?
- 35:29Speaker 3: And then you have plenty of modern PBMs out there
- 35:32Speaker 3: to provide options.
- 35:33Speaker 4: So now that they're.
- 35:34Speaker 3: Thinking about it, it's like, hey, here's some good choices
- 35:36Speaker 3: to look at. Where the legislation comes into play. I
- 35:39Speaker 3: actually don't think legislation focused on kind of correcting the
- 35:43Speaker 3: big guys is going to get us there. But it's
- 35:45Speaker 3: more legislation focused on how do we create fair competition
- 35:49Speaker 3: because that's something that we see every single day as
- 35:52Speaker 3: these big large you know, we talked about the vertical
- 35:54Speaker 3: integration on the pharmacy side, but they're integrated on the
- 35:57Speaker 3: medical side as well. And there's many times where we've
- 35:59Speaker 3: had employers that want to use Smith or X, but
- 36:02Speaker 3: they're actually blocked because of who they're choosing for their
- 36:04Speaker 3: medical provider to provide their medical benefits. And they say hey, look,
- 36:07Speaker 3: we don't We're not going to work with Smith or
- 36:09Speaker 3: X or a competitor, so we won't integrate with them
- 36:10Speaker 3: and provide the data feeds necessary. And that's sad and unfortunate,
- 36:14Speaker 3: and so I think that's that's where meaningful legislation can
- 36:17Speaker 3: really help drive change.
- 36:18Speaker 1: Yeah, and that is where the larger cost is is
- 36:21Speaker 1: on the medical side versus the pharmacy side too, so
- 36:24Speaker 1: they do kind of drive those relationships unfortunately. But yeah,
- 36:28Speaker 1: we've seen that too many times. So is your for
- 36:34Speaker 1: Smith our X is your sweet spot the self insured
- 36:36Speaker 1: employer groups then? Or do you also work with some
- 36:39Speaker 1: large TPAs? Yeah?
- 36:42Speaker 3: Are We didn't really talk about size and scope, but yeah,
- 36:45Speaker 3: so Smith or X, we've we've largely focused on the
- 36:48Speaker 3: self funded employer market.
- 36:50Speaker 4: So the vast majority of our.
- 36:51Speaker 3: Clients today are self funded employers. We have just over
- 36:56Speaker 3: forty five hundred individual employer clients, almost a million lives
- 37:00Speaker 3: that we're servicing, and it's really across the country. Some
- 37:04Speaker 3: of those do come through relationships with the TPA, where
- 37:06Speaker 3: we have a TPA partner, but the vast majority is
- 37:09Speaker 3: just again that grassroots effort of working with the individual
- 37:13Speaker 3: benefit consultants, getting them to trust our model and you know,
- 37:17Speaker 3: trust us and getting us connected with the employers.
- 37:20Speaker 1: Yeah. And is it for the health side or do
- 37:24Speaker 1: you also do workers comp aouto personal injury.
- 37:29Speaker 3: Yeah, it's primarily on the health side, the health benefits
- 37:33Speaker 3: for the employers. We have a little bit of workers
- 37:35Speaker 3: comp business, but it's not a huge core focus.
- 37:38Speaker 1: Yeah. Yeah, Okay, Well, is there anything Allan that we
- 37:43Speaker 1: haven't covered on the program that you that you feel
- 37:46Speaker 1: like is important enough that we should share with the audience.
- 37:50Speaker 3: It's a great question. I think, you know, I'm optimistic
- 37:54Speaker 3: about the future. I think, you know, finally, employers, like
- 37:57Speaker 3: we talked about, are starting to think twice about their
- 38:00Speaker 3: current situation. The you know, I mentioned the ven diagram.
- 38:04Speaker 3: I think it's starting to play out.
- 38:06Speaker 1: Right.
- 38:06Speaker 4: You have these these lawsuits.
- 38:07Speaker 3: I think you know whether or not they hold right
- 38:10Speaker 3: a few of them them have have been dismissed.
- 38:12Speaker 4: And there'll be some follow ups and back and forth.
- 38:13Speaker 3: But it's the time is here, the you know, the
- 38:19Speaker 3: the armor of the big guys is starting to fracture,
- 38:21Speaker 3: and I think there's a huge opportunity ahead of us
- 38:24Speaker 3: and it really will take you know, the community pharmacies,
- 38:28Speaker 3: the you know cohort of transparent past three PBMs that
- 38:32Speaker 3: exist all working together to really kind of push this
- 38:34Speaker 3: forward and help employers make the right decision that that
- 38:38Speaker 3: actually ends up moving the market. I do think it's
- 38:40Speaker 3: going to take employers kind of voting with their their
- 38:43Speaker 3: choice on what happens, as opposed to you know, some
- 38:45Speaker 3: meaningful mass legislation that really reigns in these.
- 38:51Speaker 4: Big guy kind of legacy PBMs.
- 38:53Speaker 1: Okay, well, what is your your role with with Smith
- 38:57Speaker 1: r X and and then let's also get some contact
- 39:01Speaker 1: information for you know, info additional information on Smith.
- 39:06Speaker 3: Yeah, so I am s VP of Product Strategy at
- 39:10Speaker 3: Smith or X.
- 39:10Speaker 4: What that what that means is all of the.
- 39:14Speaker 3: Kind of levers that we can pull in in driving
- 39:16Speaker 3: savings and value for our clients. And so my team
- 39:19Speaker 3: works on our pharmacy network that we talked a lot
- 39:21Speaker 3: about today, in contracting, our drug manufacturer relationships as well,
- 39:26Speaker 3: and then the clinical savings programs and solutions that that
- 39:29Speaker 3: we do to help navigate patients to the lowest cost
- 39:32Speaker 3: sources supply.
- 39:34Speaker 1: And and anyone can look up just SMITHARX dot com.
- 39:40Speaker 3: Yeah, exactly, it's a great starting point Smith or X
- 39:42Speaker 3: dot com. You can also look me up on LinkedIn,
- 39:45Speaker 3: Alan Paneer and you can reach out to me as well.
- 39:49Speaker 3: My My email is alandot Preneer at Smith or x
- 39:52Speaker 3: dot com. Happy to reach out and talk with anyone.
- 39:55Speaker 3: As as Breck mentioned, if if you're a community pharmacy
- 39:58Speaker 3: and you fill you're not in the best position with
- 40:01Speaker 3: Smith or X, reach out. We'd love to work with
- 40:03Speaker 3: you and do a direct contract with you and make
- 40:05Speaker 3: sure that you're in the best possible position with us.
- 40:08Speaker 1: Yeah. Well, Al, I really appreciate you coming on the
- 40:11Speaker 1: show today. You seem like a really nice guy, like
- 40:13Speaker 1: we could hang out and have talkers together or something.
- 40:15Speaker 1: So will you be at the MCPDP conference in scott
- 40:20Speaker 1: Stell in May.
- 40:22Speaker 3: We will have representatives from our team there as well,
- 40:25Speaker 3: and so yeah, look for some Smith or X folks.
- 40:27Speaker 4: They'll be there.
- 40:28Speaker 3: And yeah, Brick, we should get some red iguana next time.
- 40:31Speaker 3: You're in Salt Lake City and.
- 40:33Speaker 1: I love that place. Yeah that's great, Oh excellent. Well,
- 40:35Speaker 1: thank you so much Alan for being on the PBM
- 40:38Speaker 1: Reform podcast here on the Pharmacy Podcast Network. We look
- 40:43Speaker 1: forward to seeing more PBMs take the same approach because
- 40:49Speaker 1: you know, I'll admit I'll be one of those reformists
- 40:53Speaker 1: that have said bypass the PBMs in the past. I
- 40:57Speaker 1: have said that, but I'm a realist also and know
- 40:59Speaker 1: that that there. You know, PBMs are not going away,
- 41:03Speaker 1: but maybe we can make them more fair and take
- 41:06Speaker 1: a better approach like Smith r X has taken. So
- 41:09Speaker 1: I really appreciate you being on the show today, and
- 41:14Speaker 1: I have just a rapid fire that I'd like to
- 41:17Speaker 1: throw at you here real quick. This is just off
- 41:19Speaker 1: the cuff, but are you a Are you a morning
- 41:24Speaker 1: person or a night ol?
- 41:26Speaker 4: Oh, good question. I would say I am a morning person.
- 41:29Speaker 1: Okay, mountains or beach?
- 41:32Speaker 3: Well, I currently live near the mountains and so I
- 41:35Speaker 3: get a lot of them. So when I have a
- 41:36Speaker 3: chance to go on vacation, it's usually at the beach.
- 41:39Speaker 1: Yeah. I have a hard time with that one too.
- 41:40Speaker 1: It's because I want them both. Yeah, absolutely so. And
- 41:44Speaker 1: then the question of the of the day is coffee,
- 41:49Speaker 1: tea or something else?
- 41:51Speaker 4: Typically it is a coke zero.
- 41:54Speaker 1: There you go. Keeps me going, yeah, coke zero, Yeah,
- 41:58Speaker 1: a lot of water. My kids are so healthy, they
- 42:02Speaker 1: really keep after me. And if I'm if I'm drinking
- 42:06Speaker 1: my my preferred uh you know, pick me up used
- 42:10Speaker 1: to be red Bull, and they're like, that is so
- 42:13Speaker 1: bad for you that I'm like, well it's good though.
- 42:15Speaker 1: So anyway, so a lot of water at my at
- 42:17Speaker 1: my house. But hey, Alan, thank you so much for
- 42:19Speaker 1: being on the program, and we look forward to uh
- 42:22Speaker 1: to continuing our conversation and relationship with Smith r X.
- 42:28Speaker 1: And thank you again to our listeners again the PBM
- 42:31Speaker 1: Reform Podcast here on the Pharmacy Podcast Network. Until next time,
- 42:36Speaker 1: everyone be healthy and well. Thank you.